Phi Life Sciences Launches Licensed Prostate Mitomic Test (PMT™) for Prostate Cancer Risk
Charleston, SC, December 19, 2016 --(PR.com)-- Phi Life Sciences (Phi), a molecular diagnostic and laboratory service company that empowers physicians to deliver precision treatments and diagnostics to improve patient care and health, announced today that it has launched the Prostate Mitomic Test (PMT™) that is licensed from MDNA Life Sciences. Under the agreement, Phi is the first US partner to distribute MDNA's proprietary liquid biopsy test that evaluates the risk of high-grade prostate cancer.
PMT™ is a liquid biopsy test for the prediction of high-grade prostate cancer in advance of biopsy. It is intended for use in men with clinical suspicion of prostate cancer to determine who is likely to have high-grade cancer with a Gleason score of 7 or great that requires immediate intervention. As current clinical practice using PSA as a first-line screening tool results in many unnecessary biopsies, a follow-up test such as PMT™ can significantly aid clinicians in differentiating between men who will benefit from immediate biopsy from those who can avoid or delay such a costly and invasive procedure.
“We chose Phi as our first commercial partner to offer PMT™ due to its strong network within the molecular diagnostic space,” said Chris Mitton, CEO of MDNA Life Sciences Inc. “Launching PMT™ with Phi will allow us to quickly build a user base to drive market acceptance and adoption. This valuable partnership will also facilitate the collection of post-market data for PMT™ that will support of future publications directed to clinical utility, which will be instrumental to our reimbursement efforts in the broader US market,” he added.
“We are excited to offer MDNA’s advanced liquid-biopsy test for prostate cancer. PMT™ is a valuable addition to our test portfolio and aligns well with our vision to empower physicians to deliver more precise clinical treatments and diagnoses. PMT™ is unique in the area of prostate cancer diagnostics because it does not rely on the use of Prostate Specific Antigen detection, age, or race of a patient. It provides our clinicians the ability to evaluate a patient’s risk with a new molecular data point,” said Sawan Hurst, Chief Executive Officer of Phi Life Sciences.
About MDNA Life Sciences Inc.
MDNA Life Sciences, Inc. is leading the development of molecular diagnostic tests based on the mitochondrial genome. The Company is applying its expertise in mitochondrial genomics to continue development of an extensive and proprietary portfolio of blood-based molecular tests for conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. For more information visit www.mdnalifesciences.com
About Phi Life Sciences (Phi)
Phi is a commercialization catalyst for innovation and intends to become the leader in integrated healthcare solutions by providing best-in-class clinical products supported by robust analytics. Phi’s mission is to revolutionize traditional medical practice through the application of a broad based suite of molecular diagnostic tests. For more information visit http://www.philifesciences.com
PMT™ is a liquid biopsy test for the prediction of high-grade prostate cancer in advance of biopsy. It is intended for use in men with clinical suspicion of prostate cancer to determine who is likely to have high-grade cancer with a Gleason score of 7 or great that requires immediate intervention. As current clinical practice using PSA as a first-line screening tool results in many unnecessary biopsies, a follow-up test such as PMT™ can significantly aid clinicians in differentiating between men who will benefit from immediate biopsy from those who can avoid or delay such a costly and invasive procedure.
“We chose Phi as our first commercial partner to offer PMT™ due to its strong network within the molecular diagnostic space,” said Chris Mitton, CEO of MDNA Life Sciences Inc. “Launching PMT™ with Phi will allow us to quickly build a user base to drive market acceptance and adoption. This valuable partnership will also facilitate the collection of post-market data for PMT™ that will support of future publications directed to clinical utility, which will be instrumental to our reimbursement efforts in the broader US market,” he added.
“We are excited to offer MDNA’s advanced liquid-biopsy test for prostate cancer. PMT™ is a valuable addition to our test portfolio and aligns well with our vision to empower physicians to deliver more precise clinical treatments and diagnoses. PMT™ is unique in the area of prostate cancer diagnostics because it does not rely on the use of Prostate Specific Antigen detection, age, or race of a patient. It provides our clinicians the ability to evaluate a patient’s risk with a new molecular data point,” said Sawan Hurst, Chief Executive Officer of Phi Life Sciences.
About MDNA Life Sciences Inc.
MDNA Life Sciences, Inc. is leading the development of molecular diagnostic tests based on the mitochondrial genome. The Company is applying its expertise in mitochondrial genomics to continue development of an extensive and proprietary portfolio of blood-based molecular tests for conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. For more information visit www.mdnalifesciences.com
About Phi Life Sciences (Phi)
Phi is a commercialization catalyst for innovation and intends to become the leader in integrated healthcare solutions by providing best-in-class clinical products supported by robust analytics. Phi’s mission is to revolutionize traditional medical practice through the application of a broad based suite of molecular diagnostic tests. For more information visit http://www.philifesciences.com
Contact
Phi Life Sciences
Sawan Hurst
888-576-5445
www.philifesciences.com
Sawan Hurst
888-576-5445
www.philifesciences.com
Contact
Categories